EpiQuil presented its dissolving microneedle drug delivery platform at the UNSW Investor Showcase, connecting with investors and industry stakeholders and demonstrating its approach to delivering complex medicines through the skin.

EpiQuil has received ethics approval for its preclinical pharmacokinetic study, marking an important step in evaluating its microneedle delivery platform and supporting the next phase of development.

EpiQuil joined the Health10x Accelerator, supporting the development and commercialisation of innovative health technologies. The programme provided valuable mentorship, industry connections and opportunities to refine our clinical development and commercialisation strategy.